Show simple item record

dc.contributor.authorMorgan, D.J.
dc.date.accessioned2020-06-08T20:21:00Z
dc.date.available2020-06-08T20:21:00Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85085535847&doi=10.1093%2fcid%2fciz984&partnerID=40&md5=75e7f25ab13325fb1b583e0d1d7f35d1
dc.identifier.urihttp://hdl.handle.net/10713/12987
dc.description.abstractThis analysis summarizes a set of recent, innovative trials in infectious diseases that redefine previous, non-evidence based "rules" for antibiotics. Recent trials in infectious diseases have led to reconsidering the traditional treatment of infectious diseases by changing the duration or type of traditional antibiotics or evaluating new antibiotics for approval. These trials have used the noninferiority trial approach. The noninferiority trial design and recent infectious disease trials of relevance are discussed in this viewpoint. My objective was to analyze recent trials in infectious disease and consider needs for future trials.en_US
dc.description.urihttp://doi.org/10.1093/cid/ciz984en_US
dc.language.isoen_USen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.subjectantibioticsen_US
dc.subjectantimicrobial stewardshipen_US
dc.subjectbacteremiaen_US
dc.titleThe Overton Window and a Less Dogmatic Approach to Antibioticsen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/cid/ciz984
dc.identifier.pmid31605478


This item appears in the following Collection(s)

Show simple item record